L
0.690
0.03 (4.39%)
| Penutupan Terdahulu | 0.661 |
| Jumlah Dagangan | 43,617 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -1.84 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.16% |
| Nisbah Semasa (MRQ) | 4.86 |
| Aliran Tunai Operasi (OCF TTM) | -19.12 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -11.95 M |
| Pulangan Atas Aset (ROA TTM) | -43.68% |
| Pulangan Atas Ekuiti (ROE TTM) | -75.66% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Lantern Pharma Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | 0.0 |
| Persekitaran Makro | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | 0.40 |
|
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 14.10% |
| % Dimiliki oleh Institusi | 21.12% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Bios Capital Management, Lp | 30 Jun 2026 | 249,397 |
| Davenport & Co Llc | 30 Sep 2026 | 23,814 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |